Menu

Recent Interviews

Matthew Salthouse, CEO, Kainantu Resources

Matthew Salthouse
CEO | Kainantu Resources
3 Phillip Street #19-01 Royal Group Building, 048693 Singapore (SGP)

info@krl.com.sg

+65 6920 2020

Interview Kainantu Resources: "We hold the key to growth in the Asia-Pacific region".


Justin Reid, President and CEO, Troilus Gold Corp.

Justin Reid
President and CEO | Troilus Gold Corp.
36 Lombard Street, Floor 4, M5C 2X3 Toronto, Ontario (CAN)

info@troilusgold.com

+1 (647) 276-0050

Interview Troilus Gold: "We are convinced that Troilus is more than just a mine".


John Jeffrey, CEO, Saturn Oil + Gas Inc.

John Jeffrey
CEO | Saturn Oil + Gas Inc.
Suite 1000 - 207 9 Ave SW, T2P 1K3 Calgary (CAN)

info@saturnoil.com

+1-587-392-7900

Saturn Oil + Gas CEO John Jeffrey: "Acquisition has increased production by 2,000%"


09. September 2021 | 12:08 CET

SMA Solar, Memiontec, CureVac: Doing good and earning money

  • Investments
Photo credits: pixabay.com

When young founders develop business models, it is often a question of "purpose," i.e. the best possible (good) purpose of a company. For the new generation, money is no longer the only thing that counts. Instead, earning money and doing good are the watchwords. On the stock market, too, some companies make the world a little better. We look at three stocks and find out whether there is money to be made in them.

time to read: 3 minutes by Nico Popp
ISIN: SMA SOLAR TECHNOL.AG | DE000A0DJ6J9 , Memiontec Holdings Limited | SGXE56008290 , CUREVAC N.V. O.N. | NL0015436031


 

Author

Nico Popp

At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

About the author


SMA Solar: Thoughts after the profit warning

The share of SMA Solar recently had to give ground. The Company published a profit warning. The business with solar inverters is not going as well as planned. The expected sales are now still 10 to 12 % below the previously targeted goals. The lower sales have an even more significant impact on the expected profit: Instead of EUR 75 to 95 million, it is now expected to be EUR 50 to 65 million. If the lower figures are taken as a basis, this represents a drop of one-third. But how should investors react now?

The share price has fallen by around 15% since the profit warning. Cautious investors could wait until the price accurately reflects the lower expected earnings. But that is rarely how the stock market works. Either the market expects the lost profits to be postponed into the next year and turns earlier, or it even comes to an exaggeration. To assess this, one either dives deep into the fundamental situation at SMA Solar or orients oneself to chart technical marks. Fundamentally, the Company is supported because it has just achieved the turnaround - setbacks are typical in such a phase. In addition, the new growth course is to be supported by all three business segments, i.e. rooftop systems, commercial systems, and large-scale power plants - so there is no problem child. From a chart perspective, the share has found support above support levels between EUR 35 and 36. If this continues, the Company, which aims to be completely CO2-neutral by 2025, could take off again.

Memiontec: Clean water megatrend

Memiontec is a company that is also committed to doing good and at the same time operates in a fascinating economic region. The water treatment specialists from Singapore operate in the Asian region and have been on the market for more than twenty years. In Indonesia, in particular, the Company works with government agencies and is constantly moving projects forward. However, the Company recently won two new tenders with a total volume of SGD 12.7 million from Singapore.

As the Company is currently valued at only around EUR 60 million on the stock market, the major order caused the share price to jump. In the meantime, the share has consolidated at this level and is trending sideways. In view of the technological competence - Memiontec uses biological, chemical and physical processes for water treatment - and the general trend towards sustainability, the share can be considered an exciting growth stock. Especially in Asia, the issue of clean water is essential given rapidly growing mega-cities. Investors can make a note of Memiontec. Every new order can lead to a new valuation.

CureVac: Is a comeback on the way?

CureVac's failed first Corona vaccine project was the main reason for its revaluation. But anyone who writes the Company off because of this is making a mistake. The Tübingen-based Company still believes that it can help with possible mutations with vaccines. The mRNA technology also has many applications, such as a hope in the fight against cancer. The CureVac share has made a slight comeback in recent weeks. It will now be necessary for the stock to maintain its current level above EUR 57. The signs are good for a continuation of the recovery. However, the share is not a sure-fire winner.


Doing good and earning money - various companies combine both, and investors are spoiled for choice. While former shooting stars have yet to prove they can get back on track after setbacks, newcomers such as Memiontec's water purifiers are gradually winning over more investors. Where the journey can lead when good products meet high demand is shown by the share price performance of many former stock market shooting stars.


Author

Nico Popp

At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

16. September 2021 | 11:58 CET | by André Will-Laudien

Siemens Healthineers, PuriflOH, Fresenius, Novavax - Focusing on health!

  • Investments

The pandemic outbreak in 2020 ushered in a new era. People's health is once again moving to the center of attention. Politicians worldwide see themselves obligated to make public life safe, but whether this will be 100% successful remains questionable. Ultimately, it will depend on the commitment of private companies to what extent the existing health issues can be solved and by what means. On the capital markets, the healthcare sector has been sailing on the highest wave for months because the dangers for billions of people need to be reduced, and framework conditions for public life need to be created. Who benefits the most?

Read

14. September 2021 | 12:02 CET | by Fabian Lorenz

MorphoSys, HelloFresh, Aspermont - Price halving or rebound?

  • Investments

Investors are likely to speculate on a rebound in the Valneva share in the coming days; because the price slide of over 30% on Monday was violent. Stifel analysts see sales and earnings estimates for 2020 and 2021 in jeopardy after the UK government unexpectedly canceled a major order for the COVID-19 vaccine under development. Investors have been waiting for a rebound in MorphoSys shares for some time. The latest analyst assessment gives little hope. If Bernstein Research has its way, HelloFresh could soon be down almost 50%. Aspermont seems ripe for a rebound - the share is interesting from a chart perspective, and analysts advise buying.

Read

10. September 2021 | 11:16 CET | by Stefan Feulner

GameStop, wallstreet:online, Nikola - It goes on blithely

  • Investments

The ECB is following the lead of the FED. Although some council members warned not to ignore the risk of too high inflation, an end to the ultra-loose monetary policy is not in sight. Only the purchase of government and corporate securities under the Corona emergency purchase program should be "moderately" lower in the fourth quarter. The pro-growth decision is a balm for the stock markets. New highs should follow after the last mini-corrections.

Read